| In mammals, VGLUT1 gained a proline-rich sequence that recruits endophilinA1 and turns the transporter into a regulator of synaptic vesicles organization and spontaneous release. | A proline-rich motif on VGLUT1 reduces synaptic vesicle super-pool and spontaneous release frequency.
Zhang XM, François U, Silm K, Angelo MF, Fernandez-Busch MV, Maged M, Martin C, Bernard V, Cordelières FP, Deshors M, Pons S, Maskos U, Bemelmans AP, Wojcik SM, El Mestikawy S, Humeau Y, Herzog E., Free PMC Article | 04/11/2020 |
| The findings of this study indicate that Slc17A7 located on 1p/19q may simultaneously influence tumor development. | Network-based analysis of oligodendrogliomas predicts novel cancer gene candidates within the region of the 1p/19q co-deletion.
Gladitz J, Klink B, Seifert M., Free PMC Article | 06/8/2019 |
| Study revealed susceptibility of glutamatergic nerve terminals to Abeta induced toxicity and underlined the importance of VGLUT1 in the progression of Alzheimer's disease, as the decrease of this protein levels could increase the susceptibility to subsequent deleterious inputs by exacerbating Abeta induced neuroinflammation and synaptic plasticity disruption. | Down-regulation of glutamatergic terminals (VGLUT1) driven by Aβ in Alzheimer's disease.
Rodriguez-Perdigon M, Tordera RM, Gil-Bea FJ, Gerenu G, Ramirez MJ, Solas M. | 01/13/2018 |
| This study was the first to demonstrate an association between genetic polymorphism at rs7417284 SNP in the promoter region of the SLC17A7 gene and concussion severity and duration. Based upon these findings, rs74174284 is a potential predictive genetic marker for identifying athletes who are more susceptible for altered recovery times and worse motor speed ImPACT scores after sport-related concussion. | Genetic variation in SLC17A7 promoter associated with response to sport-related concussions.
Madura SA, McDevitt JK, Tierney RT, Mansell JL, Hayes DJ, Gaughan JP, Krynetskiy E. | 01/13/2018 |
| Results suggest that activation of JNK in Alzheimer's disease (AD) inhibits insulin signaling which could lead to a decreased expression of VGLUT1, therefore contributing to the glutamatergic deficit in AD | JNK: A Putative Link Between Insulin Signaling and VGLUT1 in Alzheimer's Disease.
Rodriguez-Perdigon M, Solas M, Ramirez MJ. | 12/17/2016 |
| Loss of SLC17A7 expression is associated with glioblastoma. | Global analysis of H3K4me3 and H3K27me3 profiles in glioblastoma stem cells and identification of SLC17A7 as a bivalent tumor suppressor gene.
Lin B, Lee H, Yoon JG, Madan A, Wayner E, Tonning S, Hothi P, Schroeder B, Ulasov I, Foltz G, Hood L, Cobbs C., Free PMC Article | 01/23/2016 |
| Depressed patients showed significant decreases in synaptophysin (SYN) and VGLUT1 expression, whereas in bipolar patients, decreases in VGLUT1 expression have also been found. | Alterations in the expression of PSA-NCAM and synaptic proteins in the dorsolateral prefrontal cortex of psychiatric disorder patients.
Gilabert-Juan J, Varea E, Guirado R, Blasco-Ibáñez JM, Crespo C, Nácher J. | 05/4/2013 |
| Data indicate that GABAergic axons were labeled with vesicular inhibitory aa transporter (VIAAT) antibodies, whereas glutamatergic axons were detected with antisera against the major vesicular glutamate transporter (VGLUT) isoforms, VGLUT1 and VGLUT2. | Glutamatergic and GABAergic innervation of human gonadotropin-releasing hormone-I neurons.
Hrabovszky E, Molnár CS, Nagy R, Vida B, Borsay BÁ, Rácz K, Herczeg L, Watanabe M, Kalló I, Liposits Z. | 08/18/2012 |
| We examined the ratio of excitatory to inhibitory vesicular neurotransmitter transporter mRNAs (VGluT1 to VGAT) and their ratio in the dorsolateral prefrontal cortex during normal human development and in people with schizophrenia | Expression of VGluT1 and VGAT mRNAs in human dorsolateral prefrontal cortex during development and in schizophrenia.
Fung SJ, Webster MJ, Weickert CS. | 08/13/2011 |
| this study suggests that the common genetic variants of the VGLUT1 gene appear not play a major role in conferring susceptibility to schizophrenia in Han population of Taiwan. | Resequencing and association study of vesicular glutamate transporter 1 gene (VGLUT1) with schizophrenia.
Shen YC, Liao DL, Chen JY, Wang YC, Lai IC, Liou YJ, Chen YJ, Luu SU, Chen CH, Shen YC, Liao DL, Chen JY, Wang YC, Lai IC, Liou YJ, Chen YJ, Luu SU, Chen CH. | 02/1/2010 |
| This study found decreased VGLUT1 mRNA expression in both major depressive disorder and bipolar disorder in the entorhinal cortex. | Vesicular glutamate transporter mRNA expression in the medial temporal lobe in major depressive disorder, bipolar disorder, and schizophrenia.
Uezato A, Meador-Woodruff JH, McCullumsmith RE. | 01/21/2010 |
| Clinical trial of gene-disease association, gene-environment interaction, and pharmacogenomic / toxicogenomic. (HuGE Navigator) | Pharmacogenetics of antipsychotic response in the CATIE trial: a candidate gene analysis.
Need AC, Keefe RS, Ge D, Grossman I, Dickson S, McEvoy JP, Goldstein DB., Free PMC Article | 02/11/2009 |
| Our results suggest that VGLUT1 expression in the prefrontal cortex could be used as a valuable neurochemical marker of dementia in AD. | Loss of VGLUT1 and VGLUT2 in the prefrontal cortex is correlated with cognitive decline in Alzheimer disease.
Kashani A, Lepicard E, Poirel O, Videau C, David JP, Fallet-Bianco C, Simon A, Delacourte A, Giros B, Epelbaum J, Betancur C, El Mestikawy S. | 01/21/2010 |
| Observational study of gene-disease association. (HuGE Navigator) | See all PubMed (2) articlesResequencing and association study of vesicular glutamate transporter 1 gene (VGLUT1) with schizophrenia.
Shen YC, Liao DL, Chen JY, Wang YC, Lai IC, Liou YJ, Chen YJ, Luu SU, Chen CH, Shen YC, Liao DL, Chen JY, Wang YC, Lai IC, Liou YJ, Chen YJ, Luu SU, Chen CH. Identification of new putative susceptibility genes for several psychiatric disorders by association analysis of regulatory and non-synonymous SNPs of 306 genes involved in neurotransmission and neurodevelopment.
Gratacòs M, Costas J, de Cid R, Bayés M, González JR, Baca-García E, de Diego Y, Fernández-Aranda F, Fernández-Piqueras J, Guitart M, Martín-Santos R, Martorell L, Menchón JM, Roca M, Sáiz-Ruiz J, Sanjuán J, Torrens M, Urretavizcaya M, Valero J, Vilella E, Estivill X, Carracedo A, Psychiatric Genetics Network Group. | 01/11/2009 |
| We found increased VGLUT1 transcript and reduced VGLUT1 protein expression in the ACC, but not DLPFC, in schizophrenia. | Altered vesicular glutamate transporter expression in the anterior cingulate cortex in schizophrenia.
Oni-Orisan A, Kristiansen LV, Haroutunian V, Meador-Woodruff JH, McCullumsmith RE., Free PMC Article | 01/21/2010 |
| Docking and homology modeling explain the inhibition of VGLUT1. | Docking and homology modeling explain inhibition of the human vesicular glutamate transporters.
Almqvist J, Huang Y, Laaksonen A, Wang DN, Hovmöller S., Free PMC Article | 01/21/2010 |
| In schizophrenia, VGLUT1 mRNA was decreased in hippocampal formation and dorsolateral prefrontal cortex. In the hippocampus, the loss of VGLUT1 mRNA supports data indicating that glutamatergic presynaptic deficits are prominent. | Decreased expression of vesicular glutamate transporter 1 and complexin II mRNAs in schizophrenia: further evidence for a synaptic pathology affecting glutamate neurons.
Eastwood SL, Harrison PJ. | 01/21/2010 |
| Alterations in the pattern of vesicular glutamate transporter 1-immunoreactivity that perfectly matched the neuronal loss and gliosis, as well as the decrease in the number of asymmetrical synapses identified by electron microscopy in this tissue | Vesicular glutamate transporter 1 immunostaining in the normal and epileptic human cerebral cortex.
Alonso-Nanclares L, De Felipe J. | 01/21/2010 |